Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
The Journal of Experimental Medicine|June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trialMatthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Pageof 12